No Data
No Data
Is Acumen Pharmaceuticals (NASDAQ:ABOS) Using Debt In A Risky Way?
Infor Acquires Acumen and Albanero
Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights From Phase 1 INTERCEPT-AD Study at the Alzheimer's Association International Conference (AAIC) 2024
Accorded Launches Latest Offering, Accorded Acumen: The Actuarial Data Transformation Platform
BTIG Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Maintains Target Price $11
Analysts' Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), Acumen Pharmaceuticals (ABOS) and DENTSPLY SIRONA (XRAY)